Aiosyn secures 2.4M funding to scale AI-powered cancer diagnostics

Radboudumc spin-off Aiosyn, a medical software company specializing in AI-powered pathology, has successfully closed a €2.4 million funding round. Participating investors are TNO Ventures, Oost NL, LUMO Labs, and Health Innovations. Alongside the funding, Aiosyn also announced a new strategic partnership with TNO, the Netherlands’ largest research and technology organization. The new funding and partnership will enable Aiosyn to accelerate the development and rollout of its AI-driven diagnostic solutions, aimed at improving cancer care through more efficient and precise pathology workflows.

Read the full release at Aiosyn’s website

• Want to know more about these subjects? Click on the buttons below for more news.

  Artificial intelligence